Treatment of Autoimmune Disease with Agonistic AntiCD137

T cells are implicated in the pathogenesis of many inflammatory diseases. To fully activate T cells, both TCR and costimulatory molecule delivered signals are required (Lanzavecchia and Sallusto, 2000). Costimulation blockade targeting various costimulatory molecules seems to be an attractive therapeutic approach for the treatment of T cell-dependent autoimmune diseases. However, these strategies appear to be prophylactic rather than therapeutic, since naive T cell activation are more dependent on costimulatory signaling while the function of preexisting autoreactive T cells are less costimulation-dependent. Another shortcoming of this approach is its requirement of repeated long-lasting treatments, which is costly. Promisingly, recent studies showed that costimulatory agonists of CD137 could prevent and have therapeutic effects on CD4+ T cell-mediated organ-specific autoimmune disease such as experimental autoimmune encephalomyelitis (EAE) and experimental autoimmune uveitis (EAU) (Shao et al., 2005; Sun et al., 2002b), and both CD4+ T cell and autoantibody-involved systemic autoimmune diseases such as systemic lupus erythematosus (SLE), collagen type II-induced arthritis (CIA) and chronic graft-versus-host disease (cGVHD) (Foell et al., 2003, 2004; Kim et al., 2005; Seo et al., 2004; Sun et al., 2002a).

Arthritis Relief and Prevention

Arthritis Relief and Prevention

This report may be oh so welcome especially if theres no doctor in the house Take Charge of Your Arthritis Now in less than 5-Minutes the time it takes to make an appointment with your healthcare provider Could you use some help understanding arthritis Maybe a little gentle, bedside manner in your battle for joint pain relief would be great Well, even if you are not sure if arthritis is the issue with you or your friend or loved one.

Get My Free Ebook


Post a comment